Should You Invest in the VanEck Biotech ETF (BBH)?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2024
0mins
Source: NASDAQ.COM
Overview of VanEck Biotech ETF (BBH): The VanEck Biotech ETF, launched in 2011, offers low-cost, diversified exposure to the Healthcare - Biotech sector, with a focus on companies involved in drug development and genetic analysis. It has assets over $457 million and an annual operating expense of 0.35%.
Performance and Rankings: As of August 2024, BBH has gained approximately 12.54% over the past year, holds a Zacks ETF Rank of 2 (Buy), and is considered a high-risk investment due to its concentrated holdings and beta of 0.74.
Analyst Views on IBB
Wall Street analysts forecast IBB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 175.160
Low
Averages
High
Current: 175.160
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
